Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Trial Profile

Double-Blind, Randomized, Historical Control Study of the Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Registrational; Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 29 Nov 2017 According to a Sunovion Pharmaceuticals media release, data of the trial will be presented at the American Epilepsy Society (AES) Annual Meeting 2017.
    • 28 Apr 2017 Results (n=271) of a post-hoc analysis from NCT01091662 and NCT00866775 studies assessing the categorical analysis of change in seizure frequency following conversion to Eslicarbazepine Acetate monotherapy, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results assessing Indices of Thyroid Function in patients from six phase III studies and their extensions (BIA2093-301,302,304,045,046,050; n=1812), presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top